RxDoctor Payments Data

Robert Scaffidi, MD

Internal Medicine · Cambridge, MANPI 1538397823

Payments from drug & device makers

$4,359in general payments, 2019–2025

Across 225 payments — averaging $19.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$720
  • Amgen$503
  • AstraZeneca$490
  • Gilead$449
  • Boehringer Ingelheim$409
  • Lilly USA, LLC$272
  • plus $2K from 17 others

What the payments were for

  • Food & beverage$4,345100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,359 in reported general payments places this provider in the 90th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$108,060
Medicare patients
240
Services billed
1,249

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban62$75,944
OzempicSemaglutide31$70,992
JardianceEmpagliflozin36$42,674
DescovyEmtricitabine/Tenofov Alafenam11$23,038
OxycontinOxycodone Hcl14$20,797
XareltoRivaroxaban12$18,461
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$16,651
FarxigaDapagliflozin Propanediol12$16,596
CreonLipase/Protease/Amylase13$15,589
TradjentaLinagliptin16$10,114
Atorvastatin Calcium445$6,668
CymbaltaDuloxetine Hcl11$5,895
Rosuvastatin Calcium120$3,490
Metoprolol Succinate150$2,910
Amlodipine Besylate319$2,663

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$720$75,94462 claims
Novo NordiskOzempic$223$70,99231 claims
Boehringer IngelheimJardiance, Tradjenta$409$52,78852 claims
GileadDescovy$449$23,03811 claims
Johnson & JohnsonXarelto$224$18,46112 claims
GSKTrelegy Ellipta$158$16,65115 claims
AstraZenecaFarxiga$490$16,59612 claims
AbbVieCreon, Synthroid$211$16,25652 claims
Lilly USA, LLCCymbalta$272$5,89511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,983 internal medicine providers in Massachusetts.

Other internal medicine in Cambridge

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →